Biopharma

EMEA-002198-PIP01-21-M01

EMEA-002198-PIP01-21-M01

Opinion/decision on a Paediatric investigation plan (PI...

Opinion/decision on a Paediatric investigation plan (PIP): Agamree, Vamorolone, ...

EMEA-002746-PIP01-20-M02

EMEA-002746-PIP01-20-M02

STAT+: House panel tees up debate over cutting Medicaid...

A House budget bill does not mention Medicaid by name, but directs the committee...

EMEA-002723-PIP01-19-M02

EMEA-002723-PIP01-19-M02

Ken Griffin’s Citadel bets £300mn against drugmaker GSK

Hedge fund’s short position is the biggest in the FTSE 100 group in more than a ...

Opinion/decision on a Paediatric investigation plan (PI...

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib...

Opinion/decision on a Paediatric investigation plan (PI...

Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, Tirzepatide...

PSUSA/00000789/202406

PSUSA/00000789/202406

CDC to lose one-tenth of workforce under Trump administ...

Nearly 1,300 probationary employees at the CDC are being forced out under the Tr...

EMEA-001716-PIP04-19-M01

EMEA-001716-PIP04-19-M01

EMEA-001625-PIP01-14-M07

EMEA-001625-PIP01-14-M07

EMEA-001619-PIP03-16-M02

EMEA-001619-PIP03-16-M02

Moderna shoulders $238M contract manufacturing cancella...

In 2024’s fourth quarter, Moderna’s cost of sales came out to $739 million, whic...

Boston biotech Bambusa banks $90M for next-gen bispecifics

Bambusa Therapeutics has raised about $90 million to build out a pipeline of nex...

PSUSA/00002163/202407

PSUSA/00002163/202407

EMEA-001716-PIP07-22

EMEA-001716-PIP07-22

PSUSA/00000989/202406

PSUSA/00000989/202406

EMEA-003467-PIP01-23

EMEA-003467-PIP01-23

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir...

Opinion/decision on a Paediatric investigation plan (PI...

Opinion/decision on a Paediatric investigation plan (PIP): Enerzair Breezhaler, ...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Zinforo, ceftaroline f...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Karvea, irbesartan, Da...

Allogene’s phase 1 lymphoma data show CAR-T could ‘leap...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts ha...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.